Are combination therapies the future of renal cell carcinoma treatment?
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
Checkpoint blockers for skin cancer - effects in the periphery vs the central sites
Negative results from trial of roniciclib compared to platinum-based chemotherapy for SCLC
Key messages from the immune checkpoint inhibitors session